Legend Biotech (LEGN) has recently garnered attention by assembling a team of advisors in oncology and cell therapy to refine its research priorities. The stock has seen a significant short-term rebound, with a 12.34% one-day return and a 59.06% increase over the past 90 days, although it is still down 20.66% over the past year. Currently valued at $4.36 billion and trading at $26.50, analysts believe the stock is undervalued with a fair value estimate of $57.24, suggesting potential for growth. However, there are concerns about competition in the multiple myeloma market and reliance on R&D partnerships, which increases execution risk. Despite some mixed signals regarding its valuation metrics, Legend Biotech remains a stock to watch, especially as it prepares to present at the upcoming Cell & Gene Meeting on the Mediterranean.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-valuation-check-as-new-scientific-adviso
